Novartis Licenses AVEO Oncology’s Antibody to Treat Metabolic Syndrome
Novartis will develop AVEO’s AV-380, an investigational humanized antibody targeting growth differentiation factor 15.
Novartis will develop AVEO Oncology’s first-in-class humanized antibody targeting growth differentiation factor 15 (GDF15), a proinflammatory cytokine. According to a press release from AVEO, AVEO could stand to earn up to $326 million for the deal, which includes a $15-million upfront payment and milestone payments of up to $311 million.
The antibody will be developed and investigated for its efficacy in treating wasting syndrome (e.g., weight and muscle loss), which is typically associated with chronic diseases such as cancer, chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. The metabolic condition, commonly known as Cachexia, is also associated with the clinical manifestation of anemia, inflammation, and suppression of immune functions.
Novartis will retain rights to all products and derivative products through the partnership and will be responsible for the commercialization and manufacturing of the medication and associated products.
Source: AVEO
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
